The Prevalence of Immediate Hypersensitivity Reactions to the BNT162b2 mRNA Vaccine against SARS-CoV-2: Data from the Vaccination Campaign in a Large Academic Hospital
The anti-SARS-CoV-2 vaccination has probably been the most effective tool for preventing the infection and negative outcomes of the COVID-19 disease, and therefore for interrupting the pandemic state. The first licensed SARS-CoV-2 vaccine was BNT162b2, an mRNA vaccine that has been widely used since...
Main Authors: | Giovanni Paoletti, Jack Pepys, Maria Chiara Bragato, Sandro Paoletti, Alessandra Piona, Maria Rita Messina, Francesca Racca, Sebastian Ferri, Emanuele Nappi, Giovanni Costanzo, Lorenzo Del Moro, Francesca Puggioni, Giorgio Walter Canonica, Elena Azzolini, Enrico Heffler |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-04-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/11/5/903 |
Similar Items
-
Polyethylene Glycol and Polysorbate 80 Skin Tests in the Context of an Allergic Risk Assessment for Hypersensitivity Reactions to Anti-SARS-CoV-2 mRNA Vaccines
by: Emanuele Nappi, et al.
Published: (2023-04-01) -
Desensitization Protocols for Anti-SARS-CoV-2 Vaccines in Patients with High Risk of Allergic Reactions
by: Maria Rita Messina, et al.
Published: (2023-04-01) -
Drugs and Vaccines Hypersensitivity in Children with Mastocytosis
by: Francesca Mori, et al.
Published: (2022-06-01) -
Anaphylatoxin Complement 5a in Pfizer BNT162b2-Induced Immediate-Type Vaccine Hypersensitivity Reactions
by: Xin Rong Lim, et al.
Published: (2023-05-01) -
Late Hypersensitivity Reactions to the BNT162b2 SARS-CoV-2 Vaccine Are Linked to Delayed Skin Sensitization and Prior Exposure to Hyaluronic Acid
by: Ramit Maoz-Segal, et al.
Published: (2022-12-01)